Table 1.
Clinical parameters of the study population
| Continuous variable | Number of biopsy sessions | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 (n=79) | 2 (n=146) | 3 (n=84) | ⩾4 (n=64) | P | Total (n=373) | ||||||
| Mean | Median | Mean | Median | Mean | Median | Mean | Median | Mean | Median | ||
| Age at biopsy | 62.7 | 63.9 | 63.0 | 62.5 | 64.1 | 64.0 | 66.4 | 66.5 | 0.011 | 63.8 | 64.2 |
| Prebiopsy PSA | 5.6 | 4.8 | 7.0 | 5.4 | 9.1 | 8.6 | 13.6 | 9.3 | <0.001 | 8.3 | 6.3 |
| Body mass index | 28.5 | 28.0 | 29.0 | 27.8 | 28.3 | 27.8 | 28.6 | 28.1 | 0.767 | 28.7 | 27.9 |
| No. of prior biopsy cores | — | — | 13.7 | 12.0 | 25.3 | 20.0 | 37.9 | 30.5 | <0.001 | 22.3 | 12.0 |
| Categorical variables | Count (%) | Count (%) | Count (%) | Count (%) | P | Count (%) |
|---|---|---|---|---|---|---|
| Prebiopsy TURP | 1 (1.3) | 0 (0) | 1 (1.2) | 5 (7.8) | 0.001 | 366 (98.1) |
| Prebiopsy diagnosis | ||||||
| PIN | 0 (0) | 9 (6.2) | 4 (4.8) | 5 (7.8) | <0.001 | 18 (4.8) |
| Elevated PSA | 79 (100) | 109 (74.7) | 62 (73.8) | 46 (71.9) | 296 (79.4) | |
| ASAP | 0 (0) | 28 (19.2) | 18 (21.4) | 13 (20.3) | 59 (15.8) | |
| Tobacco | ||||||
| Never | 38 (48.1) | 72 (49.2) | 40 (47.6) | 31 (48.4) | 0.724 | 181 (48.5) |
| Former | 31 (39.2) | 53 (36.3) | 35 (41.7) | 29 (45.3) | 148 (39.7) | |
| Current | 10 (12.7) | 21 (14.4) | 9 (10.7) | 4 (6.3) | 44 (11.8) | |
| Hypertension | 33 (41.8) | 75 (50.3) | 34 (40.5) | 32 (50.0) | 0.377 | 174 (46.3) |
| Diabetes | 3 (3.8) | 24 (16.4) | 11 (13.1) | 6 (9.4) | 0.039 | 44 (11.8) |
Abbreviations: ASAP, atypical small acinar proliferation; PIN, prostatic intraepithelial neoplasia; PSA, prostate specific antigen; TURP, transurethral resection of the prostate.
Bold indicates statistically significant.